Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Killing 2 birds with 1 stone in DLBCL

R. Eric Davis

Blood (2021) 138 (10): 822–824.

https://doi.org/10.1182/blood.2021011933

Published: 2021

Journal Articles

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

Junling Zhuang, Fazal Shirazi, Ram Kumar Singh, Isere Kuiatse, Hua Wang, Hans C. Lee, Zuzana Berkova, Allison Berger, Marc Hyer, Nibedita Chattopadhyay, Sakeena Syed, Judy Qiuju Shi, Jie Yu, Vaishali Shinde, Stephen Tirrell, Richard Julian Jones, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski

Blood (2019) 133 (14): 1572–1584.

https://doi.org/10.1182/blood-2018-06-859686

Published: 2019

Includes: Supplemental data

Journal Articles

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Blood (2018) 132 (Supplement 1): 4020.

https://doi.org/10.1182/blood-2018-99-117310

Published: 2018

Journal Articles

Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia

Seemana Bhattacharya, PhD, Sujan Piya, PhD, Qi Zhang, PhD, Natalia Baran, PhD MD, Teresa McQueen, MS, R. Eric Davis, MD, Nicholas Cosford, PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 3934.

https://doi.org/10.1182/blood-2018-99-114817

Published: 2018

Journal Articles

Adoptive T-Cell Therapy with TCL1-Specific TCR for B-Cell Lymphomas

Jinsheng Weng, MD PhD, Kelsey Moriarty, BD, Yong Pan, Man Chun John MA, PhD, Rohit Mathur, PhD, Zheng Zhang, Hiroki Torikai, MD, Sourindra N Maiti, Fuliang Chu, PhD, Xiaoyun Cheng, Swathi Karri, Deepshika Medapalli, Laurence J N Cooper, MD PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD

Blood (2018) 132 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2018-99-115424

Published: 2018

Journal Articles

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Natalia Baran, PhDMD, Teresa McQueen, MS, R. Eric Davis, MD, Yimin Qian, PhD, Kanak Raina, PhD, M. James You, MD PhD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 890.

https://doi.org/10.1182/blood-2018-99-115692

Published: 2018

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML

Shelley Herbrich, MS, Keith Baggerly, PhD, Gheath Alatrash, DO, PhD, R. Eric Davis, MD, Michael Andreeff, MD PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 2768.

https://doi.org/10.1182/blood-2018-99-114818

Published: 2018

Journal Articles

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

Nathan H. Fowler, MD, Preetesh Jain, MBBS,MDDM,PhD, Loretta J. Nastoupil, MD, F. B. Hagemeister, MD, Sheryl G Forbes, Lore Lagrone, Luis Fayad, MD, Hun Ju Lee, MD, R. Eric Davis, MD, Jason R. Westin, MD, Michael Wang, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD

Blood (2018) 132 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2018-99-119592

Published: 2018

Journal Articles

HSP110 and MYD88: blame the chaperone

R. Eric Davis

Blood (2018) 132 (5): 462–463.

https://doi.org/10.1182/blood-2018-06-857532

Published: 2018

Journal Articles

Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): A Novel Strategy Targeting FLT3 Double Mutant and Non-FLT3 Mutant AML Progenitor/Stem Cells

Jo Ishizawa, MD PhD, Ran Zhao, Lauren Heese, Alex Jaeger, PhD, Yuki Nishida, Rodrigo Jacamo, PhD, Kensuke Kojima, MD PhD, Man Chun John MA, PhD, Vivian Ruvolo, PhD, Dhruv Chachad, R. Eric Davis, MD, William Devine, PhD, John A Porco, Jr., PhD, Luke Whitesell, MD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2637.

https://doi.org/10.1182/blood.V130.Suppl_1.2637.2637

Published: 2017

Journal Articles

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Jason R. Westin, MD, Yasuhiro Oki, MD, Loretta Nastoupil, MD, Luis Fayad, MD, Sattva S. Neelapu, MD, Francesco Turturro, MD, F. B. Hagemeister, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, MD, Ken H. Young, MD PhD, Timothy J. McDonnell, MD PhD, Richard J. Ford, MD PhD, R. Eric Davis, MD

Blood (2017) 130 (Supplement 1): 189.

https://doi.org/10.1182/blood.V130.Suppl_1.189.189

Published: 2017

Journal Articles

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Loretta Nastoupil, MD, Jason R. Westin, MD, Nathan H. Fowler, MD, Michelle A. Fanale, MD, Felipe Samaniego, MD, Yasuhiro Oki, MD, Ly Dsouza, PA-C, Chizobam Obi, RN, JingJing Cao, Xiaoyun Cheng, Man Chun John MA, PhD, Wang Zhiqiang, Lei Feng, MS, Shouhao Zhou, R. Eric Davis, MD, Sattva S. Neelapu, MD

Blood (2017) 130 (Supplement 1): 414.

https://doi.org/10.1182/blood.V130.Suppl_1.414.414

Published: 2017

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific, Centyrin TM -Based, PiggyBac TM -Transposed CAR-T Memory Stem Cells Are Effective Against p53 -/- and Patient-Derived Multiple Myeloma Tumors

Blood (2017) 130 (Supplement 1): 3068.

https://doi.org/10.1182/blood.V130.Suppl_1.3068.3068

Published: 2017

Journal Articles

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Elisabet E. Manasanch, MD, Rohit Mathur, PhD, Hans C. Lee, MD, Donna M. Weber, MD, Krina K. Patel, MDMSc, Sheeba K. Thomas, MD, Silvia C. Munoz, RN, Claudia Morales de Partovi, Catherine M. Claussen, MS, Pei Lin, MDDM,MDC, Behrang Amini, MD, Linghua Wang, Man Chun John MA, PhD, Yun Qing, Feng Lei, MS, Veera Baladandayuthapani, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Robert Z. Orlowski, MD PhD

Blood (2017) 130 (Supplement 1): 3089.

https://doi.org/10.1182/blood.V130.Suppl_1.3089.3089

Published: 2017

Journal Articles

Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Rohit Mathur, PhD, Zheng Zhang, Jin He, Roman Galetto, PhD, Agnès Gouble, PhD, Isabelle Chion-Sotinel, Stéphanie Filipe, PhD, Annabelle Gariboldi, Tanooha Veeramachaneni, Elisabet E. Manasanch, MD, Sheeba K. Thomas, MD, Hans C. Lee, MD, Krina K. Patel, MDMSc, Donna M. Weber, MD, R. Eric Davis, MD, Robert J. Orlowski, MD PhD, Julianne Smith, PhD, Jing Yang, PhD, Sattva S. Neelapu, MD

Blood (2017) 130 (Supplement 1): 502.

https://doi.org/10.1182/blood.V130.Suppl_1.502.502

Published: 2017

Journal Articles

Tonic B-cell receptor signaling in diffuse large B-cell lymphoma

Ondrej Havranek, Jingda Xu, Stefan Köhrer, Zhiqiang Wang, Lisa Becker, Justin M. Comer, Jared Henderson, Wencai Ma, John Man Chun Ma, Jason R. Westin, Dipanjan Ghosh, Nicholas Shinners, Luhong Sun, Allen F. Yi, Anusha R. Karri, Jan A. Burger, Tomasz Zal, R. Eric Davis

Blood (2017) 130 (8): 995–1006.

https://doi.org/10.1182/blood-2016-10-747303

Published: 2017

Includes: Multimedia, Supplemental data

Journal Articles

Ibrutinib inhibits pre-BCR + B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK

Ekaterina Kim, Christian Hurtz, Stefan Koehrer, Zhiqiang Wang, Sriram Balasubramanian, Betty Y. Chang, Markus Müschen, R. Eric Davis, Jan A. Burger

Blood (2017) 129 (9): 1155–1165.

https://doi.org/10.1182/blood-2016-06-722900

Published: 2017

Includes: Supplemental data

Journal Articles

Noninvasive Detection of BCL2 , BCL6 , and MYC Translocations in Diffuse Large B-Cell Lymphoma

Blood (2016) 128 (22): 2930.

https://doi.org/10.1182/blood.V128.22.2930.2930

Published: 2016

NARROW

Killing 2 birds with 1 stone in DLBCL

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia

Adoptive T-Cell Therapy with TCL1-Specific TCR for B-Cell Lymphomas

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

HSP110 and MYD88: blame the chaperone

Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): A Novel Strategy Targeting FLT3 Double Mutant and Non-FLT3 Mutant AML Progenitor/Stem Cells

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

B-Cell Maturation Antigen (BCMA)-Specific, Centyrin TM -Based, PiggyBac TM -Transposed CAR-T Memory Stem Cells Are Effective Against p53 -/- and Patient-Derived Multiple Myeloma Tumors

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Tonic B-cell receptor signaling in diffuse large B-cell lymphoma

Ibrutinib inhibits pre-BCR + B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK

Noninvasive Detection of BCL2 , BCL6 , and MYC Translocations in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only